Jasper Therapeutics (JSPR) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Initiated Coverage | Overweight | $2.00 | Aug 12, 2026 |
| RBC Capital | Maintained | Sector Perform | $3.00 from $4.00 | May 15, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | May 15, 2026 |
| Evercore ISI Group | Maintained | Outperform | $7.00 from $12.00 | Apr 1, 2026 |
| UBS | Initiated Coverage | Neutral | $1.50 | Mar 23, 2026 |
| RBC Capital | Maintained | Sector Perform | $4.00 from $5.00 | Nov 11, 2025 |
| BTIG | Maintained | Buy | $7.00 from $20.00 | Sep 22, 2025 |
| Evercore ISI Group | Maintained | Outperform | $14.00 from $20.00 | Sep 22, 2025 |
| JMP Securities | Maintained | Market Outperform | $6.00 from $12.00 | Sep 22, 2025 |
| UBS | Maintained | Buy | $25.00 from $29.00 | Aug 15, 2025 |
| Evercore ISI Group | Maintained | Outperform | $20.00 from $50.00 | Jul 8, 2025 |
| JMP Securities | Maintained | Market Outperform | $12.00 from $70.00 | Jul 8, 2025 |
| BMO Capital | Downgraded | Outperform → Market Perform | $4.00 from $15.00 | Jul 8, 2025 |
| BTIG | Maintained | Buy | $20.00 from $64.00 | Jul 7, 2025 |
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | — | Jul 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $40.00 | Jul 7, 2025 |
| William Blair | Downgraded | Outperform → Market Perform | — | Jul 7, 2025 |
| Oppenheimer | Maintained | Outperform | $65.00 from $80.00 | May 15, 2025 |
| UBS | Maintained | Buy | $33.00 from $38.00 | May 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Mar 11, 2025 |
Frequently asked questions
Is JSPR a buy, sell, or hold?
Analysts covering Jasper Therapeutics currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on JSPR?
On Aug 12, 2026, Piper Sandler initiated coverage of Jasper Therapeutics at Overweight with a price target of $2.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.